Domain III of the envelope protein as a dengue vaccine target

Expert Rev Vaccines. 2010 Feb;9(2):137-47. doi: 10.1586/erv.09.139.

Abstract

A dengue vaccine should induce long-lasting, simultaneous protection to the four dengue viruses while avoiding the immune enhancement of viral infection. Domain III of the dengue envelope protein has been implicated in receptor binding, and is also the target of specific neutralizing antibodies. Domain III has emerged as a promising region for a subunit vaccine candidate. Here, we review the current state of knowledge on vaccine candidates based on domain III. Due to the results obtained concerning the immune response and protection in mice and monkeys, particular attention is paid to the chimeric protein domain III fused to p64k of Neisseria meningitidis.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / immunology
  • Antigens, Viral / immunology*
  • Bacterial Outer Membrane Proteins / genetics
  • Bacterial Outer Membrane Proteins / immunology
  • Dengue / prevention & control*
  • Dengue Vaccines / immunology*
  • Haplorhini
  • Humans
  • Mice
  • Protein Structure, Tertiary
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / immunology
  • Vaccines, Subunit / genetics
  • Vaccines, Subunit / immunology
  • Viral Envelope Proteins / immunology*
  • Virus Attachment

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Antigens, Viral
  • Bacterial Outer Membrane Proteins
  • Dengue Vaccines
  • Recombinant Fusion Proteins
  • Vaccines, Subunit
  • Viral Envelope Proteins
  • lpdA protein, Neisseria meningitidis